Hilton Hotels Corporation Common Stock (HLT) Stock Price Today
Aura AI Summary
Key Stats
- $82.43BMarket Cap
- 1,732,329Volume
- Consumer CyclicalSector
- $376.5352W High
- $264.3252W Low
- 140 DaysTypical Hold Time
- $95.62BEnterprise Value
- 0.16%Div Yield
- -Trading Activity
Track Hilton Hotels Corporation Common Stock (HLT) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Hilton Hotels Corporation Common Stock has traded between a low of $264.32 and a high of $376.53, highlighting its annual price range. Buy and sell Hilton Hotels Corporation Common Stock shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Most Recent News
Roche unveils new Alzheimer’s drug and diagnostic data at CTAD 2026, advancing treatment and early detection.
Roche presented new data on its Alzheimer’s disease portfolio at the CTAD 2026 conference, highlighting advances in both pharmaceuticals and diagnostics. Key updates include Phase Ib/IIa data for trontinemab showing rapid amyloid clearance, the start...

Valneva's chikungunya vaccine IXCHIQ® shows 94% antibody persistence five years after one dose
Valneva announced that 94% of participants maintained a strong antibody response five years after a single dose of its chikungunya vaccine IXCHIQ®. The vaccine showed durable immunity across all age groups, including adults over 65, supporting its po...

Valneva's chikungunya vaccine IXCHIQ® shows 94% antibody persistence five years after one dose
Valneva SE reported that 94% of participants maintained a strong immune response five years after a single dose of its chikungunya vaccine IXCHIQ®. The vaccine showed durable antibody persistence across all age groups, including those over 65, suppor...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.